

Reference:	FOI.15250.24
Subject:	Treatment of inflammatory diseases
Date of Request:	10 September 2024

Your request and our response

1. How many patients were treated with the following drugs from the following departments (for any disease) from the start of Apr 2024 to the end of Jun 2024?
Please use the latest available 3 months if April to June is not available and specify which 3 months has been used.

Hywel Dda University Health Board (UHB) provides, within the table below as requested, the number of Dermatology, Gastroenterology and Rheumatology patients, treated with the listed medications, for any disease, during the period 1 April to 30 June 2024.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab	77	146	288
Apremilast	9	0	30
Baricitinib	*	0	69
Bimekizumab	*	0	0
Brodalumab	*	0	0
Certolizumab Pegol	*	0	41
Deucravacitinib	0	0	0
Etanercept	*	0	217
Etrasimod	0	0	0
Filgotinib	0	*	*
Golimumab	0	0	31
Guselkumab	*	0	0
Infliximab (Biosimilars)	0	83	19
Infliximab (Remicade)	0	*	0
Ixekizumab	0	0	9
Mirikizumab	0	0	0
Ozanimod	0	*	0
Risankizumab	17	8	*
Rituximab	0	*	28
Sarilumab	0	0	7
Secukinumab	29	0	45
Tildrakizumab	*	0	0
Tocilizumab	0	0	91
Tofacitinib	0	*	*
Upadacitinib	*	27	17
Ustekinumab	20	119	12
Vedolizumab	0	104	6

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection

Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

2. How many patients were treated with Ustekinumab and its biosimilars from the following departments (for any disease) from the start of Jun 2024 to the end of Aug 2024?
Please use the latest available 3 months if June to August is not available and specify which 3 months has been used.

The UHB provides, within the table overleaf as requested, the number of Dermatology, Gastroenterology and Rheumatology patients, treated with the listed medications, for any disease, during the period 1 April to 30 June 2024.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Ustekinumab (Stelara)	21	116	11
Ustekinumab (Pyzchiva)	0	0	0
Ustekinumab (Uzpruvo)	0	0	0
Ustekinumab (Wezenla)	0	0	0
Ustekinumab (Stelara)	0	0	0